143 related articles for article (PubMed ID: 32232655)
1. Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging.
Hahn F; Müller L; Jungmann F; Mähringer-Kunz A; Tanyildizi Y; Düber C; Galle PR; Weinmann A; Kloeckner R
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1883-1890. PubMed ID: 32232655
[TBL] [Abstract][Full Text] [Related]
2. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.
Konstantinidis IT; Do RK; Gultekin DH; Gönen M; Schwartz LH; Fong Y; Allen PJ; D'Angelica MI; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
Ann Surg Oncol; 2014 Aug; 21(8):2675-83. PubMed ID: 24664624
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma.
Lee BS; Lee SH; Son JH; Jang DK; Chung KH; Paik WH; Ryu JK; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):493-500. PubMed ID: 26220764
[TBL] [Abstract][Full Text] [Related]
4. Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.
Wang L; Deng M; Ke Q; Lou J; Zheng S; Bi X; Wang J; Guo W; Li F; Wang J; Zheng Y; Li J; Cheng S; Zhou W; Zeng Y
Cancer Med; 2020 Apr; 9(8):2674-2685. PubMed ID: 32072774
[TBL] [Abstract][Full Text] [Related]
5. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Wiazzane N; Chauffert B; Ghiringhelli F
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):614-8. PubMed ID: 23711827
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Chae H; Cho H; Yoo C; Kim KP; Jeong JH; Chang HM; Kang J; Lee HC; Lim YS; Kim KM; Shim JH; Lee SS; Park DH; Song TJ; Hwang S; Song GW; Moon DB; Lee YJ; Lee JH; Ryoo BY
Int J Biol Markers; 2018 Nov; 33(4):432-438. PubMed ID: 29874985
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma.
Sutton TL; Billingsley KG; Walker BS; Enestvedt CK; Dewey EN; Orloff SL; Mayo SC
Am J Surg; 2021 Jun; 221(6):1182-1187. PubMed ID: 33707077
[TBL] [Abstract][Full Text] [Related]
9. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma.
Panettieri E; Maki H; Kim BJ; Kang HC; Cox V; Vega EA; Mizuno T; Pant S; Javle M; Vauthey JN; Kawaguchi Y
Surg Oncol; 2022 Mar; 40():101696. PubMed ID: 34995974
[TBL] [Abstract][Full Text] [Related]
10. Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system.
Hahn F; Müller L; Mähringer-Kunz A; Schotten S; Düber C; Hinrichs JB; Maschke SK; Galle PR; Bartsch F; Lang H; Weinmann A; Kloeckner R
PLoS One; 2020; 15(2):e0228501. PubMed ID: 32012198
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
Liguori C; Copparoni C; Felicetti C; Pecci F; Lupi A; Pinterpe G; Berardi R; Giampieri R
Curr Oncol; 2023 Jan; 30(1):1032-1045. PubMed ID: 36661728
[TBL] [Abstract][Full Text] [Related]
12. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels.
Lin ZY; Liang ZX; Zhuang PL; Chen JW; Cao Y; Yan LX; Yun JP; Xie D; Cai MY
BMC Cancer; 2016 Oct; 16(1):792. PubMed ID: 27733196
[TBL] [Abstract][Full Text] [Related]
14. The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?
Hahn F; Müller L; Stöhr F; Mähringer-Kunz A; Schotten S; Düber C; Bartsch F; Lang H; Galle PR; Weinmann A; Kloeckner R
Liver Int; 2019 Jul; 39(7):1307-1314. PubMed ID: 31070868
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
[TBL] [Abstract][Full Text] [Related]
17. Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma.
Sur MD; In H; Sharpe SM; Baker MS; Weichselbaum RR; Talamonti MS; Posner MC
Ann Surg Oncol; 2015 Jul; 22(7):2209-17. PubMed ID: 25476031
[TBL] [Abstract][Full Text] [Related]
18. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience.
Hyder O; Marques H; Pulitano C; Marsh JW; Alexandrescu S; Bauer TW; Gamblin TC; Sotiropoulos GC; Paul A; Barroso E; Clary BM; Aldrighetti L; Ferrone CR; Zhu AX; Popescu I; Gigot JF; Mentha G; Feng S; Pawlik TM
JAMA Surg; 2014 May; 149(5):432-8. PubMed ID: 24599477
[TBL] [Abstract][Full Text] [Related]
19. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
[TBL] [Abstract][Full Text] [Related]
20. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
